31.47

0.00% 0.00

Catalyst Pharmaceuticals Inc (CPRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CPRX Giù? Forum Previsione

Precedente Chiudi:

$31.47

Aprire:

$31.47

Volume 24 ore:

1.35M

Relative Volume:

0.59

Capitalizzazione di mercato:

$3.85B

Reddito:

$596.96M

Utile/perdita netta:

$221.32M

Rapporto P/E:

18.09

EPS:

1.7397

Flusso di cassa netto:

$208.13M

1 W Prestazione:

+0.06%

1M Prestazione:

+0.41%

6M Prestazione:

+38.51%

1 anno Prestazione:

+44.03%

Intervallo 1D:

$31.47

$31.48

Intervallo di 1 settimana:

$31.45

$31.50

Portata 52W:

$19.05

$32.56

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Nome

Catalyst Pharmaceuticals Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

(305) 529-2522

Indirizzo

355 ALHAMBRA CIRCLE, CORAL GABLES

Dipendente

182

Cinguettio

@CatalystForRare

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CPRX Catalyst Pharmaceuticals Inc	31.47	3.85B	596.96M	221.32M	208.13M	1.7397
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-04	Iniziato	Robert W. Baird	Outperform
2024-11-18	Iniziato	Stephens	Overweight
2024-03-14	Iniziato	Citigroup	Buy
2024-03-07	Iniziato	BofA Securities	Buy
2023-12-21	Iniziato	Oppenheimer	Outperform
2022-08-24	Downgrade	ROTH Capital	Buy → Neutral
2018-09-21	Iniziato	Cantor Fitzgerald	Overweight
2018-09-07	Ripresa	Piper Jaffray	Overweight
2016-10-05	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-04-26	Downgrade	Piper Jaffray	Overweight → Neutral
2014-09-30	Reiterato	ROTH Capital	Buy
2014-09-16	Reiterato	ROTH Capital	Buy
2014-09-15	Reiterato	H.C. Wainwright	Buy
2013-10-21	Reiterato	Aegis Capital	Buy
2013-09-24	Iniziato	Maxim Group	Buy
2013-09-06	Reiterato	Aegis Capital	Buy
2013-04-18	Iniziato	Aegis Capital	Buy
2012-08-27	Aggiornamento	Rodman & Renshaw	Mkt Perform → Mkt Outperform
2009-10-01	Aggiornamento	Merriman	Sell → Neutral
2009-05-29	Downgrade	Hapoalim	Neutral → Underperform
2009-05-29	Downgrade	Merriman Curhan Ford	Buy → Sell
2008-12-15	Iniziato	Merriman Curhan Ford	Buy
2007-11-28	Iniziato	Rodman & Renshaw	Mkt Outperform
2007-01-31	Iniziato	Stifel Nicolaus	Buy
2007-01-05	Iniziato	First Albany	Buy

Mostra tutto

Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie

Jul 10, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth - ChartMill

Jul 10, 2026

Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger - Yahoo Finance

Jul 10, 2026

Jul 09, 2026

Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion - Pluang

Jul 09, 2026

Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal - Stock Titan

Jul 08, 2026

Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary - Quartr

Jul 08, 2026

Catalyst Pharmaceuticals focuses on rare neuromuscular diseases as a specialized Nasdaq biotech - ad-hoc-news.de

Jul 08, 2026

Jul 05, 2026

Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data - Sahm

Jul 05, 2026

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn - Investing.com

Jul 05, 2026

Jul 02, 2026

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - The Globe and Mail

Jul 02, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength - ChartMill

Jul 02, 2026

Jul 01, 2026

CPRXCatalyst Pharmaceuticals Inc Earnings - Finviz

Jul 01, 2026

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE® - NTB Kommunikasjon

Jul 01, 2026

Jun 30, 2026

Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression - Stock Titan

Jun 30, 2026

Catalyst reports Phase 1 vamorolone study results - Investing.com

Jun 30, 2026

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses - The Manila Times

Jun 30, 2026

Catalyst reports Phase 1 vamorolone study results By Investing.com - Investing.com Canada

Jun 30, 2026

Vamorolone Demonstrates On-Target Glucocorticoid Activity - GlobeNewswire

Jun 30, 2026

Jun 29, 2026

Monolithic Power Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Monolithic Power Systems, Inc.MPWR - Business Wire

Jun 29, 2026

Skeletal Nickel Catalyst Market Growth to Accelerate by 2035 Amid Rising Pharma DemandNews and Statistics - IndexBox

Jun 29, 2026

Jun 28, 2026

Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus

Jun 28, 2026

Quantified Common Ground Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus

Jun 28, 2026

Jun 27, 2026

Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In - Sahm

Jun 27, 2026

Jun 26, 2026

Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x - TechStock²

Jun 26, 2026

Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Price to book forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Jun 25, 2026

Understanding the Setup: (CPRX) and Scalable Risk - Stock Traders Daily

Jun 25, 2026

Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 25, 2026

Nationwide Renaissance Small Cap Growth Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus

Jun 25, 2026

Jun 24, 2026

Catalyst Pharmaceuticals stock edges higher to 31.41 after patient summit event, CatalystForRare - Traders Union

Jun 24, 2026

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - Business Wire

Jun 24, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC - ChartMill

Jun 24, 2026

Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger - Sahm

Jun 24, 2026

Jun 23, 2026

Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger – Key Details from 8-K Filing - Minichart

Jun 23, 2026

Catalyst Pharma Gains FTC Clearance for Angelini Merger - TipRanks

Jun 23, 2026

Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026 - TradingView

Jun 23, 2026

HSR waiting period ends for Catalyst (NASDAQ: CPRX) and Angelini Pharma merger - Stock Titan

Jun 23, 2026

Jun 22, 2026

Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares - AD HOC NEWS

Jun 22, 2026